pH-Operated Nanopistons on the Surfaces of Mesoporous Silica Nanoparticles

The development of drug delivery systems for the targeted and on-demand release of pharmaceutical products has risen rapidly to become a contemporary challenge in the field of nanobiotechnology. Biocompatible mechanized phosphonate-clothed silica nanoparticles have been designed and fabricated in which the supramolecular machinery, which covers the surfaces of the nanoparticles, behaves like nanopistons, releasing encapsulated guest molecules in a controlled fashion under acidic conditions. The mechanized nanoparticles consist of a monolayer of beta-cyclodextrin (beta-CD) rings positioned selectively around the orifices of the nanopores of the mesoporous nanoparticles. A rhodamine B/benzidine conjugate was prepared for use as the nanopistons for movement in and out of the cylindrical cavities provided by the beta-CD rings on the surfaces of the nanoparticles. Luminescence experiments indicated that the mechanized nanoparticles were able to store small cargo molecules (e.g., 2,6-naphthalenedisulfonic acid disodium) within their nanopores at neutral pH and then release them by passage through the cavities of the beta-CD rings as soon as the pH was lowered to similar to 5. In further investigations, the phosphonate-covered silica nanoparticles were functionalized selectively with the beta-CD rings, but on this occasion, the seven linkers attaching the rings to the orifices surrounding the nanopores contained cleavable imine double bonds. The beta-CD rings on the surface of the nanoparticles served as gates for the storage of large cargo molecules (e.g., rhodamine B) inside the nanopores of the nanoparticles under neutral conditions. Since imine bonds can be hydrolyzed under acidic conditions, the beta-CD rings could be severed from the surface of the nanoparticles when the pH was decreased to 6, releasing the large cargo molecules. The results described here present a significant step toward the development of pH-responsive nanoparticle-based dual drug delivery vehicles that are potentially capable of being interfaced with biological systems.